The ALTU-237 Phase I clinical trial was a single-center, double-blind, placebo-controlled, dose escalating study. The primary objective was to evaluate the safety and tolerability of ALTU-237 in healthy
The completed Phase I trial was a dose escalation study to establish the safety and immunologic activity of AE37 in 15 node-negative breast cancer patients. The patients received
The companies have also received approval from the regulatory authorities in Denmark to initiate a second repeat-dose Phase I clinical trial of TB-403 in patients with advanced solid
The multi-center, open-label, Phase II study had two arms, irinotecan-naive (IRI-naive) and irinotecan-refractory (IRI-refractory). IRI-naive patients had less than or equal to two prior regimens; one adjuvant/neoadjuvant and
Under this agreement, WuXi AppTec will provide the relevant viruses, materials and methodologies to Sartorius Stedim Biotech to employ in conducting non good laboratory practice (GLP) viral clearance
LX1032 is one of four programs in human clinical trials as part of Lexicon’s 10TO10 program. Having completed a single-dose Phase Ia clinical trial, Lexicon will initiate a
The US patents do not expire until 2019. The lawsuit is based upon an abbreviated new drug application (ANDA) filed by Watson seeking FDA approval for a generic
The Invisicare patent provides protection in the areas of topical composition, topical composition precursor, and methods for manufacturing and using. This patent will assist Skinvisible’s sales efforts in
The agreement was signed following Foamix’s successful development of non-steroidal foam which is designed to help skin barrier properties. Under the terms of the agreement, Foamix will be
The collaboration aims to combine Immune Disease Institute (IDI) immunological expertise with GlaxoSmithKline’s (GSK’s) pharmaceutical capabilities within a competitive framework. The partnership will be pioneering in the way
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.